News | Atrial Fibrillation | November 15, 2016

Atrial Fibrillation Patients at Increased Risk of Dementia Regardless of Anticoagulation Use

Study results suggest the way heart rhythms are treated could have impact on all forms of dementia

atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016

November 15, 2016 — Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of developing dementia than patients who use warfarin for non-atrial fibrillation conditions, according to a new study from the Intermountain Medical Center Heart Institute.

Atrial fibrillation is an abnormal heart rhythm that raises the risk of small clots forming in the heart and leading to a stroke. Warfarin is the most common anticoagulant drug used worldwide to lower risk of the harmful clots from forming and causing stroke.

For the study, Intermountain researchers looked at more than 6,000 patients who had no history of dementia and were chronically anticoagulated using warfarin for any indication – not just atrial fibrillation. The patients were then divided into two groups: those with atrial fibrillation who were using warfarin, and those using warfarin who did not have atrial fibrillation.

After adjusting for multiple variations, patients with atrial fibrillation were two to three times more likely to develop dementia compared to the patients who were on warfarin, but did not have a diagnosis of atrial fibrillation.

“Atrial fibrillation patients are at higher risk of developing all forms of dementia compared to patients without atrial fibrillation. Warfarin is used to lower risk of stroke in patients with atrial fibrillation, but when the blood levels of the drug are erratic it contributes to the dementia risk. This dementia risk is observed in people with and without atrial fibrillation that are exposed to long-term warfarin treatment” said Jared Bunch, M.D., lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City.

“Even when we consider the influence of warfarin on dementia risk, the presence of atrial fibrillation conveys additional risk of dementia. This suggests that they way we manage the abnormal heart rhythm, beyond just the practice of preventing blood clots through warfarin, may be a way we can further lower the risk of all forms of dementia, including Alzheimer’s disease, in patients with atrial fibrillation,” Bunch added.

Results of the study were presented during the American Heart Association Scientific Sessions, Nov. 12-16 in New Orleans.

Seven years ago, researchers from the Intermountain Medical Center Heart Institute found that patients with atrial fibrillation had much higher rates of all forms of dementia, including Alzheimer’s disease. Since then, researchers have continued to explore the association between atrial fibrillation and dementia in an effort to better understand and identify ways to prevent dementia in heart patients.

“Further research is needed to identify the many complex mechanisms that link atrial fibrillation to dementia,” said Bunch. “We are initiating a series of new studies that are aimed to understand what treatments may reduce the risk of developing dementia in atrial fibrillation patients.”

Other members of the Intermountain Medical Center Heart Institute team include Kevin Graves, BS; Heidi T. May, Ph.D.; Tami L. Bair, RN; Victoria Jacobs, Ph.D.; Brian G. Crandall, M.D.; Michael Cutler, M.D.; Jeffrey S. Osborn, M.D.; Charles Mallender, M.D.; John D. Day, M.D.; and Peter Weiss, M.D.

The Intermountain Medical Center is the flagship facility for the Intermountain Healthcare system, which is based in Salt Lake City.

For more information: www.scientificsessions.org

Related Content

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Overlay Init